TCMP
NBIX icon

Thrive Capital Management (Pennsylvania)’s Neurocrine Biosciences NBIX Stock Holding History

Thrive Capital Management (Pennsylvania)’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.62M Sell
27,428
-439
-2% -$65.1K 0.87% 42
2026
Q1 		$3.67M Buy
27,867
+3,987
+17% +$529K 0.8% 58
2025
Q4 		$3.39M Buy
23,880
+7,563
+46% +$1.1M 0.75% 69
2025
Q3 		$2.29M Buy
16,317
+940
+6% +$127K 0.59% 76
2025
Q2 		$1.93M Buy
15,377
+11,175
+266% +$1.28M 0.61% 72
2025
Q1 		$465K Sell
4,202
-6,974
-62% -$883K 0.28% 84
2024
Q4 		$1.53M Buy
11,176
+7,121
+176% +$881K 0.7% 62
2024
Q3 		$467K Buy
4,055
+77
+2% +$10.6K 0.22% 128
2024
Q2 		$548K Buy
3,978
+2,225
+127% +$305K 0.25% 110
2024
Q1 		$242K Buy
+1,753
New +$239K 0.13% 102

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Thrive Capital Management (Pennsylvania)'s NBIX Position: Q2 2026 in Review

Thrive Capital Management (Pennsylvania) reduced its Neurocrine Biosciences (NBIX) stake by 1.6% in Q2 2026, selling an estimated $65.1K and leaving 27,428 shares worth $4.62M. The position accounts for 0.87% of the portfolio, ranked #42.

Thrive Capital Management (Pennsylvania) first reported a position in NBIX in Q1 2024 and has held it in 10 quarters since. 781 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Thrive Capital Management (Pennsylvania) held 27,428 shares of Neurocrine Biosciences worth $4.62M as of Q2 2026.
  • Thrive Capital Management (Pennsylvania) sold 439 Neurocrine Biosciences shares in Q2 2026, an estimated $65.1K.
  • Neurocrine Biosciences made up 0.87% of Thrive Capital Management (Pennsylvania)'s portfolio in Q2 2026, its #42 holding.
  • Thrive Capital Management (Pennsylvania) first reported a position in Neurocrine Biosciences in Q1 2024 and has held it in 10 quarters since.
  • 781 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Thrive Capital Management (Pennsylvania)'s 13F filing for Q2 2026, filed 5 Aug 2026.